Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01224665 · ClinicalTrials.gov registry record · NA

S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

A NA study, sponsored by SWOG Cancer Research Network.

Completed
Registry status
NA
Development phase
658
Enrollment target

NCT01224665 is a NA study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 658 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01224665, a NA study, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
NA
Development phase
658 participants
Enrollment target

Study Summary

RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer. It is not yet known whether extended pelvic lymphadenectomy is more effective than standard pelvic lymphadenectomy during surgery. PURPOSE: This randomized phase II trial is studying standard pelvic lymphadenectomy to see how well it works compared to extended pelvic lymphadenectomy in treating patients undergoing surgery for invasive bladder cancer.

Interventions

  • PROCEDURE therapeutic conventional surgery
  • PROCEDURE therapeutic standard lymphadenectomy
  • PROCEDURE therapeutic extended lymphadenectomy

Trial Details

FieldValue
Enrollment Target 658 participants
Start Date 2011-11-25
Est. Completion 2024-05
Phase NA

Sponsor

SWOG Cancer Research Network

270 total trials

What the Registry Record Tells You About NCT01224665

The ClinicalTrials.gov registry entry for NCT01224665 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 658 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which therapeutic conventional surgery is the first listed.

NCT01224665 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01224665 about?

NCT01224665 is a clinical study titled "S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer". RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer. It is not yet known whether extended pelvic lymphadenectomy is more effective than standard pelvic lymphadenectomy during surgery. PURPOSE: This randomized phase II tri...

What is the current status of trial NCT01224665?

This trial is currently completed. It is a NA study. The enrollment target is 658 participants. The study started on 2011-11-25. Estimated completion is 2024-05.

What interventions are being tested in trial NCT01224665?

The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), therapeutic standard lymphadenectomy (PROCEDURE), therapeutic extended lymphadenectomy (PROCEDURE).

Who is sponsoring clinical trial NCT01224665?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.